Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma

  • Michishita Masaki
    Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan
  • Uto Tatsuya
    Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan
  • Nakazawa Ryota
    Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan
  • Yoshimura Hisashi
    Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan
  • Ogihara Kikumi
    Department of Pathology, School of Life and Environmental Science, Azabu University, Japan
  • Naya Yuko
    Department of Pathology, School of Life and Environmental Science, Azabu University, Japan
  • Tajima Tsuyoshi
    Department of Veterinary Pharmacology, Nippon Veterinary and Life Science University, Japan
  • Azakami Daigo
    Department of Veterinary Nursing, Nippon Veterinary and Life Science University, Japan
  • Kishikawa Seigo
    Department of Pathology, School of Life and Environmental Science, Azabu University, Japan
  • Arai Toshiro
    Department of Veterinary Biochemistry, Nippon Veterinary and Life Science University, Japan
  • Takahashi Kimimasa
    Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan

この論文をさがす

説明

Canine hemangiopericytoma (CHP) is characterized by frequent local recurrence and increased invasiveness. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis in tumors. The aim of the present study was to investigate the effect of a single dose of bevacizumab on a xenograft model of CHP. VEGF protein was secreted from cultured CHP cells and interacted with bevacizumab. Bevacizumab treatment suppressed tumor growth by inhibiting tumor angiogenesis, whereas no significant differences were observed in the proliferation index and apoptosis rates of treated and untreated mice. Thus, bevacizumab had antitumor effects in a xenograft model of CHP.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (26)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ